Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. NeuroFrontiers

Alzheimer’s Research: Opening the Blood-Brain Barrier with Aducanumab and Focused Ultrasound

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    A recent phase 1 study investigated the safety and feasibility of combining focused ultrasound and aducanumab, which is a monoclonal antibody for amyloid, to open the blood-brain barrier in patients with Alzheimer's disease. And what the researchers found was about a 50 percent overall reduction of cerebral amyloid-beta load in the target areas compared to the untreated areas. Dive further into these findings and next steps in this line of research that may impact the way we treat Alzheimer’s disease with Dr. Andrew Wilner and Dr. Marc Haut, Director of the Rockefeller Neuroscience Institute’s Memory Health Clinic at West Virginia University.

Recommended
Details
Presenters
Comments
  • Overview

    A recent phase 1 study investigated the safety and feasibility of combining focused ultrasound and aducanumab, which is a monoclonal antibody for amyloid, to open the blood-brain barrier in patients with Alzheimer's disease. And what the researchers found was about a 50 percent overall reduction of cerebral amyloid-beta load in the target areas compared to the untreated areas. Dive further into these findings and next steps in this line of research that may impact the way we treat Alzheimer’s disease with Dr. Andrew Wilner and Dr. Marc Haut, Director of the Rockefeller Neuroscience Institute’s Memory Health Clinic at West Virginia University.

Schedule12 Nov 2024